112 related articles for article (PubMed ID: 1720828)
1. Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans.
Camenzind E; Nussberger J; Juillerat L; Munafo A; Fischli W; Coassolo P; van Brummelen P; Kleinbloesem CH; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1991 Sep; 18(3):299-307. PubMed ID: 1720828
[TBL] [Abstract][Full Text] [Related]
2. Renin release regulation during acute renin inhibition in normal volunteers.
Ménard J; Guyene TT; Chatellier G; Kleinbloesem CH; Bernadet P
Hypertension; 1991 Sep; 18(3):257-65. PubMed ID: 1889841
[TBL] [Abstract][Full Text] [Related]
3. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.
van den Meiracker AH; Admiraal PJ; Derkx FH; Kleinbloesem C; Man in 't Veld AJ; van Brummelen P; Mulder P; Schalekamp MA
J Hypertens; 1993 Aug; 11(8):831-8. PubMed ID: 8228207
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
5. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
6. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
Hagmann M; Nussberger J; Naudin RB; Burns TS; Karim A; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1997 Apr; 29(4):444-50. PubMed ID: 9156352
[TBL] [Abstract][Full Text] [Related]
7. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
[TBL] [Abstract][Full Text] [Related]
8. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.
van den Meiracker AH; Admiraal PJ; Man in 't Veld AJ; Derkx FH; Ritsema van Eck HJ; Mulder P; van Brummelen P; Schalekamp MA
BMJ; 1990 Jul; 301(6745):205-10. PubMed ID: 2203486
[TBL] [Abstract][Full Text] [Related]
9. Ro 42-5892 is a potent orally active renin inhibitor in primates.
Fischli W; Clozel JP; el Amrani K; Wostl W; Neidhart W; Stadler H; Branca Q
Hypertension; 1991 Jul; 18(1):22-31. PubMed ID: 1830563
[TBL] [Abstract][Full Text] [Related]
10. Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081.
Noël B; Del Re G; Capone P; Brunner HR; Nussberger J
J Cardiovasc Pharmacol; 1996 Aug; 28(2):252-8. PubMed ID: 8856481
[TBL] [Abstract][Full Text] [Related]
11. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition.
Mooser V; Nussberger J; Juillerat L; Burnier M; Waeber B; Bidiville J; Pauly N; Brunner HR
J Cardiovasc Pharmacol; 1990 Feb; 15(2):276-82. PubMed ID: 1689424
[TBL] [Abstract][Full Text] [Related]
12. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II.
Nussberger J; Brunner DB; Waeber B; Brunner HR
Life Sci; 1988; 42(17):1683-8. PubMed ID: 2835564
[TBL] [Abstract][Full Text] [Related]
13. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients.
Jeunemaître X; Ménard J; Nussberger J; Guyene TT; Brunner HR; Corvol P
Am J Hypertens; 1989 Nov; 2(11 Pt 1):819-27. PubMed ID: 2686709
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers.
Nussberger J; Delabays A; De Gasparo M; Cumin F; Waeber B; Brunner HR; Ménard J
Hypertension; 1989 Jun; 13(6 Pt 2):948-53. PubMed ID: 2661435
[TBL] [Abstract][Full Text] [Related]
15. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
16. Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men.
Doig JK; MacFadyen RJ; Meredith PA; Fischli W; Reid JL
J Cardiovasc Pharmacol; 1992 Dec; 20(6):875-80. PubMed ID: 1282588
[TBL] [Abstract][Full Text] [Related]
17. Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact.
Derkx FH; van den Meiracker AH; Fischli W; Admiraal PJ; Man in't Veld AJ; van Brummelen P; Schalekamp MA
Am J Hypertens; 1991 Jul; 4(7 Pt 1):602-9. PubMed ID: 1873015
[TBL] [Abstract][Full Text] [Related]
18. Effects of chronic infusion of renin inhibitor A-64662 in sodium-depleted monkeys.
Verburg KM; Kleinert HD; Kadam JR; Chekal MA; Mento PF; Wilkes BM
Hypertension; 1989 Mar; 13(3):262-72. PubMed ID: 2646217
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
Azizi M; Guyene TT; Chatellier G; Ménard J
J Hypertens; 1994 Apr; 12(4):419-27. PubMed ID: 8064166
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I.
Inglessis N; Nussberger J; Hagmann M; Hiesse-Provost O; Insuasty J; Reid J; Ménard J; Brunner HR
J Cardiovasc Pharmacol; 1995 Jun; 25(6):986-93. PubMed ID: 7564346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
